IWWM-11 2022 | An insight into a novel MYD88 transgenic model being used to investigate WM
Ruben Carrasco
• 28 Oct 2022
Ruben Carrasco, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into a novel MYD88 transgenic model being used to investigate mutations in Waldenström’s macroglobulinemia (WM). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
